The cytotoxic drugs contract manufacturing market refers to the outsourcing of the production of cytotoxic drugs to specialized contract manufacturing organizations (CMOs). These CMOs provide services such as formulation development, process optimization, and large-scale production of cytotoxic drugs for pharmaceutical companies. The market is driven by factors such as the increasing prevalence of cancer worldwide, the growing demand for personalized medicine, and the need for cost-effective drug manufacturing solutions. Additionally, the rising investments in research and development activities and the advancements in technology are further propelling the market growth.
The global Cytotoxic Drugs Contract Manufacturing Market size is estimated to be valued at US$ 6,285.2 million in 2018 and is expected to exhibit a CAGR of 9.1% between 2023 and 2030.
Prominent Companies in the cytotoxic drugs contract manufacturing Industry:
1) Lonza Group: Lonza Group, founded in 1897, is headquartered in Basel, Switzerland. With over 15,500 employees, the company operates in more than 35 countries. Lonza Group specializes in the development and manufacturing of a wide range of products, including cytotoxic drugs. One major key insight of the company is its strong expertise in process optimization and quality control, ensuring the production of high-quality cytotoxic drugs.
SWOT Analysis:
Strength: Lonza Group has a strong global presence and a diverse portfolio of products and services.
Weakness: The company may face challenges in meeting the increasing demand for cytotoxic drugs due to capacity constraints.
Opportunity: Lonza Group can capitalize on the growing demand for personalized medicine and the outsourcing trend in the pharmaceutical industry.
Threats: The company faces competition from other contract manufacturing organizations and regulatory challenges in different countries.
Key Developments:
- In November 2022, Lonza has launched an innovative new capsule solution for intestinal (enteric) drug delivery. The Capsugel® Enprotect™ capsule does not disintegrate during stomach transit and only releases its contents in the intestine. Capsugel® Enprotect™ capsules significantly simplify the drug product manufacturing process by mitigating the need for additional capsule coating or sealing.
- In July 2022, Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, announced the completion of its planned cGMP clinical and commercial drug product manufacturing line in Visp (CH).
- In September 2021, Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced it will invest in additional drug product manufacturing capabilities in Switzerland.
2) Piramal Group: Piramal Group, founded in 1984, is headquartered in Mumbai, India. With over 10,000 employees, the company operates in more than 30 countries. Piramal Group offers a wide range of services, including contract manufacturing of cytotoxic drugs. One major key insight of the company is its strong focus on quality assurance and regulatory compliance, ensuring the production of safe and effective cytotoxic drugs.
SWOT Analysis:
Strength: Piramal Group has a strong presence in the Indian market and a diverse portfolio of healthcare products and services.
Weakness: The company may face challenges in expanding its global footprint and competing with established international players.
Opportunity: Piramal Group can leverage its expertise in contract manufacturing to tap into the growing demand for cytotoxic drugs in emerging markets.
Threats: The company faces competition from both domestic and international contract manufacturing organizations and changing regulatory landscapes.
Key Developments:
- In September 2022, Piramal Pharma Limited Consumer Products Division (CPD) has announced the launch of its D2C platform, Wellify.in. It is an exclusive, one-stop shop for all the health and wellness brand offerings by the company, and is expected to contribute 10% of the e-commerce business in terms of revenue by end of FY24
3) Evonik Industries AG: Evonik Industries AG, founded in 2007, is headquartered in Essen, Germany. With over 32,000 employees, the company operates in more than 100 countries. Evonik Industries AG specializes in specialty chemicals and offers contract manufacturing services for cytotoxic drugs. One major key insight of the company is its strong focus on innovation and sustainability, driving the development of novel manufacturing processes for cytotoxic drugs.
SWOT Analysis:
Strength: Evonik Industries AG has a strong global presence and a diverse portfolio of specialty chemicals and contract manufacturing services.
Weakness: The company may face challenges in adapting to changing market dynamics and customer requirements.
Opportunity: Evonik Industries AG can capitalize on the increasing demand for targeted therapies and the development of novel drug delivery systems.
Threats: The company faces competition from other contract manufacturing organizations and the risk of regulatory non-compliance.
Key Developments:
In March 2023, Evonik has officially begun construction of its $220 million global-scale production facility for pharmaceutical specialty lipids in Lafayette, Indiana, in the United States.
4) Novasep Holding SAS: Novasep Holding SAS, founded in 1995, is headquartered in Lyon, France. With over 1,200 employees, the company operates in more than 20 countries. Novasep Holding SAS specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and offers contract manufacturing services for cytotoxic drugs. One major key insight of the company is its strong expertise in chromatography and purification technologies, ensuring the production of high-purity cytotoxic drugs.
SWOT Analysis:
Strength: Novasep Holding SAS has a strong reputation in the pharmaceutical industry and a wide range of capabilities in API manufacturing and contract manufacturing services.
Weakness: The company may face challenges in scaling up production to meet the increasing demand for cytotoxic drugs.
Opportunity: Novasep Holding SAS can leverage its expertise in purification technologies to offer cost-effective and high-quality contract manufacturing solutions.
Threats: The company faces competition from other contract manufacturing organizations and the risk of supply chain disruptions.
Key Development:
In April 2022, PharmaZell, a supplier of highly resilient and specialty APIs, and Novasep, a major CDMO focused on complex small molecules and ADCs, announced the closing of their merger, following exclusive negotiations initiated in September 2021. This strategic merger creates a technology driven, leading CDMO and API manufacturer
5) Merck KGaA (SAFC Pharma): Merck KGaA, founded in 1668, is headquartered in Darmstadt, Germany. With over 57,000 employees, the company operates in more than 60 countries. Merck KGaA offers a wide range of products and services, including contract manufacturing of cytotoxic drugs through its SAFC Pharma division. One major key insight of the company is its strong focus on innovation and collaboration, driving the development of novel drug manufacturing technologies.
SWOT Analysis:
Strength: Merck KGaA has a long history and a strong global presence, with a diverse portfolio of products and services.
Weakness: The company may face challenges in adapting to changing market dynamics and customer requirements.
Opportunity: Merck KGaA can leverage its expertise in biopharmaceutical manufacturing to tap into the growing demand for cytotoxic drugs.
Threats: The company faces competition from other contract manufacturing organizations and the risk of regulatory non-compliance.
Key Development:
In October 2021, Merck, a science and technology company, announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint.
6) Baxter Biopharma Solutions: Baxter Biopharma Solutions, founded in 1931, is headquartered in Deerfield, Illinois, USA. With over 48,000 employees, the company operates in more than 100 countries. Baxter Biopharma Solutions specializes in the development and manufacturing of biopharmaceuticals, including cytotoxic drugs. One major key insight of the company is its strong focus on patient safety and product quality, ensuring the production of safe and effective cytotoxic drugs.
SWOT Analysis:
Strength: Baxter Biopharma Solutions has a strong global presence and a diverse portfolio of biopharmaceutical products and services.
Weakness: The company may face challenges in meeting the increasing demand for cytotoxic drugs due to capacity constraints.
Opportunity: Baxter Biopharma Solutions can capitalize on the growing demand for targeted therapies and the outsourcing trend in the pharmaceutical industry.
Threats: The company faces competition from other contract manufacturing organizations and the risk of supply chain disruptions.
Key Developments:
In November 2021, Baxter International Inc. , a global marketer in sterile medication production and delivery, announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany.
7) AbbVie Contract Manufacturing: AbbVie Contract Manufacturing, founded in 2013, is headquartered in North Chicago, Illinois, USA. With over 30,000 employees, the company operates in more than 170 countries. AbbVie Contract Manufacturing offers a wide range of services, including contract manufacturing of cytotoxic drugs. One major key insight of the company is its strong focus on quality control and regulatory compliance, ensuring the production of high-quality cytotoxic drugs.
SWOT Analysis:
Strength: AbbVie Contract Manufacturing has a strong reputation in the pharmaceutical industry and a diverse portfolio of products and services.
Weakness: The company may face challenges in expanding its global footprint and competing with established international players.
Opportunity: AbbVie Contract Manufacturing can leverage its expertise in contract manufacturing to tap into the growing demand for cytotoxic drugs in emerging markets.
Threats: The company faces competition from both domestic and international contract manufacturing organizations and changing regulatory landscapes.
8) Cambrex Corporation: Cambrex Corporation, founded in 1981, is headquartered in East Rutherford, New Jersey, USA. With over 1,200 employees, the company operates in more than 20 countries. Cambrex Corporation specializes in the development and manufacturing of small molecule active pharmaceutical ingredients (APIs) and offers contract manufacturing services for cytotoxic drugs. One major key insight of the company is its strong expertise in chemical synthesis and process optimization, ensuring the production of high-quality cytotoxic drugs.
SWOT Analysis:
Strength: Cambrex Corporation has a strong reputation in the pharmaceutical industry and a wide range of capabilities in API manufacturing and contract manufacturing services.
Weakness: The company may face challenges in scaling up production to meet the increasing demand for cytotoxic drugs.
Opportunity: Cambrex Corporation can leverage its expertise in chemical synthesis to offer cost-effective and high-quality contract manufacturing solutions.
Threats: The company faces competition from other contract manufacturing organizations and the risk of supply chain disruptions.
Key Developments:
In March 2022 – Cambrex, a global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, announced it is significantly expanding its existing biopharmaceutical testing services business.
9) BSP Pharmaceuticals S.p.A.: BSP Pharmaceuticals S.p.A., founded in 2000, is headquartered in Latina, Italy. With over 300 employees, the company operates in more than 40 countries. BSP Pharmaceuticals S.p.A. specializes in the development and manufacturing of sterile injectable products, including cytotoxic drugs. One major key insight of the company is its strong focus on quality assurance and regulatory compliance, ensuring the production of safe and effective cytotoxic drugs.
SWOT Analysis:
Strength: BSP Pharmaceuticals S.p.A. has a strong reputation in the pharmaceutical industry and a diverse portfolio of sterile injectable products and contract manufacturing services.
Weakness: The company may face challenges in expanding its global footprint and competing with established international players.
Opportunity: BSP Pharmaceuticals S.p.A. can capitalize on the increasing demand for cytotoxic drugs and the outsourcing trend in the pharmaceutical industry.
Threats: The company faces competition from other contract manufacturing organizations and the risk of regulatory non-compliance.
10) CordenPharma International: CordenPharma International, founded in 2006, is headquartered in Liestal, Switzerland. With over 1,500 employees, the company operates in more than 10 countries. CordenPharma International offers a wide range of services, including contract manufacturing of cytotoxic drugs. One major key insight of the company is its strong focus on customer satisfaction and flexibility, providing customized contract manufacturing solutions for cytotoxic drugs.
Key Developments:
In March 2023, MSD chooses Italy to invest 200 million dollars over the next ten years aimed at accelerating research and development in the oncological area. The American multinational leader in the pharmaceutical sector, in Italy since 1956, confirms and expands its commitment and its presence in the country in line with its mission of 'Inventing for Life'. This is thanks to the partnership signed with Bsp Pharmaceuticals Sp,A.
SWOT Analysis:
Strength: CordenPharma International has a strong global presence and a diverse portfolio of products and services.
Weakness: The company may face challenges in meeting the increasing demand for cytotoxic drugs due to capacity constraints.
Opportunity: CordenPharma International can leverage its expertise in contract manufacturing to tap into the growing demand for cytotoxic drugs in emerging markets.
Threats: The company faces competition from other contract manufacturing organizations and the risk of supply chain disruptions.
Key Developments:
- In January 2023, CordenPharma has announce the signing of a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.
- In February 2022, CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A.
